Malignant Hypertension and Bilateral Primary Aldosteronism

Intern Med. 2023 Sep 15;62(18):2675-2680. doi: 10.2169/internalmedicine.1098-22. Epub 2023 Feb 1.

Abstract

Malignant hypertension triggers incremental renin activity, whereas primary aldosteronism suppresses such activity. We encountered a patient with malignant hypertension refractory to multiple anti-hypertensive agents. Repeated neurohormonal assessments, instead of a single one, eventually uncovered trends in an incremental aldosterone concentration, ranging from 221 up to 468 pg/mL, with a decline in the renin activity from 2.3 to <0.2 ng/mL/h. Adrenal venous sampling confirmed bilateral aldosterone secretion. Following the diagnosis of bilateral primary aldosteronism, we initiated a mineralocorticoid receptor antagonist, which improved his blood pressure. Repeated neurohormonal assessments are encouraged to correctly diagnose underlying primary aldosteronism with malignant hypertension.

Keywords: adrenal venous sampling; blood pressure; mineralocorticoid receptor antagonist.

MeSH terms

  • Aldosterone
  • Humans
  • Hyperaldosteronism* / complications
  • Hyperaldosteronism* / diagnosis
  • Hypertension* / diagnosis
  • Hypertension* / drug therapy
  • Hypertension* / etiology
  • Hypertension, Malignant* / complications
  • Hypertension, Malignant* / diagnosis
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Renin

Substances

  • Aldosterone
  • Renin
  • Mineralocorticoid Receptor Antagonists